Abstract:
본 발명은 트롬빈 수용체 길항제인 신규한 크로멘 유도체, 이의 약학적으로 허용가능한 염 또는 이의 이성질체, 이의 제조방법 및 이를 포함하는 PAR-1 관련 질환의 예방 또는 치료용 약학적 조성물에 관한 것이다. 본 발명의 크로멘 유도체는 PAR-1 길항 효과를 우수하게 나타내므로, PAR-1 관련 질환의 예방 또는 치료용 약학적 조성물, 길항제로써, 관상동맥 질환, 맥혈전증, 뇌혈관질환 또는 동맥경화, 혈관재협착, 혈액 응고, 고혈압, 부정맥, 협심증, 심부전 등을 포함하는 심혈관 질환을 포함하는 혈전 관련 질환, 염증 또는 암의 예방 또는 치료에 사용될 수 있다.
Abstract:
PURPOSE: A pharmaceutical composition containing novel chromeme derivative, pharmaceutically acceptable salts or isomers thereof is provided to prevent or treat blood clot-related diseases or cancer. CONSTITUTION: A chromene derivative is denoted by chemical formula 1. A pharmaceutical composition for preventing or treating PAR-1 activation-related diseases contains the chromene derivative, pharmaceutically acceptable salt, isomer as an active ingredient. A pharmaceutical composition for cardiovascular disease treatment aid contains the chromene derivative, pharmaceutically acceptable salt, or isomer as an active ingredient. A PAR-1 antagonist contains the chromene derivative, pharmaceutically acceptable salt, or isomer as an active ingredient.
Abstract:
본 발명은 신규한 피리딘을 포함하는 알킬로 치환된 인덴 유도체, 이의 약학적으로 허용가능한 염 또는 이의 이성질체, 이의 제조방법 및 이를 포함하는 PAR-1 관련 질환의 치료용 약학적 조성물에 관한 것이다. 본 발명의 인덴 유도체는 PAR-1 길항 효과를 우수하게 나타내므로, PAR-1 관련 질환의 예방 또는 치료용 약학적 조성물, 길항제로써, 관상동맥 질환, 맥혈전증, 뇌혈관질환 또는 동맥경화, 혈관재협착, 혈액 응고, 고혈압, 부정맥, 협심증, 심부전 등을 포함하는 심혈관 질환을 포함하는 혈전 관련 질환, 염증 또는 암의 예방 또는 치료에 사용될 수 있다.
Abstract:
본 발명은 하기 화학식 1의 신규한 [6+5]접합 바이사이클 유도체, 약제학적으로 허용되는 그의 염 또는 이성질체, 그의 제조방법 및 그를 포함하는 약제학적 조성물에 관한 것이다. 화학식 1의 [6+5]접합 바이사이클 유도체는 트롬빈 수용체를 길항하여 단독, 또는 다른 심혈관계 치료제와 병용투여하여 혈전, 혈소판 응집, 동맥경화, 혈관재협착, 혈액 응고, 고혈압, 부정맥, 협심증, 심부전, 염증 및 암의 치료제로 유용하게 사용될 수 있다. [화학식 1]
Abstract:
PURPOSE: A pharmaceutical composition containing an alkyl-substituted indene derivative containing novel pyridine, or pharmaceutically acceptable salts or isomers thereof is provided to prevent or treat PAR-1 related diseases, inflammation, or cancer. CONSTITUTION: An alkyl-substituted indene derivative containing pyridine is denoted by chemical formula 1. A pharmaceutical composition for preventing or treating PAR-1 activation-related diseases contains the indene derivative, salts, or isomers as an active ingredient. A pharmaceutical composition for cardiovascular treatment aid is alternately used with cardiovascular drugs such as aspirin, clopidogrel, ticlopidine, abciximab, or tirofiban.
Abstract:
(a) reacting 1,3- diketo cpds. with hydrazine derivs. in solvnet i.e. C1-6 alcohol, C1-6 alkylcyano cpds. or these mixt. to form 5-pyrazolone derivs.; (b) reacting with metal carbonate and acylhalide to form 4-acryl-5- hydroxypyrazole derivs.; and (c) reacting with 4-toluene sulfonyl chloride. The rxn. carried out in an vessel. Prepg. cpds. are useful as a herbicide.
Abstract:
The present invention relates to novel chromene derivatives as thrombin receptor antagonist, pharmaceutically acceptable salts or isomer thereof, a method for preparing the same, and a pharmaceutical composition for preventing or treating PAR-1 related diseases, containing the same as an active ingredient. The chromene derivatives of the present invention exhibit an excellent PAR-1 antagonistic effect, and thus can be used for a pharmaceutical composition for preventing or treating PAR-1 related diseases and can be used, as an antagonist, in preventing or treating thrombosis-related diseases, inflammation, or cancers, including coronary artery diseases, vein thrombosis, cerebrovascular diseases, cardiovascular diseases such as atherosclerosis, restenosis, blood clots, high blood pressure, arrhythmia, angina, and heart failure, and the like.
Abstract:
PURPOSE: A novel [6+5]fused bicycle derivative and a pharmaceutical composition containing the same are provided to be used as a therapeutic agent for treating platelet aggregation, arteriosclerosis, vascular restenosis, blood clotting, and hypertension. CONSTITUTION: A novel [6+5]fused bicycle derivative is denoted by chemical formula 1. A method for preparing the composition of chemical formula 1 comprises a step of reacting compounds of chemical formulas 2 and 3 or reacting compounds of chemical formulas 4 and 5. A PAR-1 antagonist composition contains the compound of chemical formula 1, pharmaceutically acceptable salt thereof, or pharmaceutically acceptable carrier.